UY39574A - Compuesto macrocíclico útil para tratar el cáncer y composición farmacéutica que lo contiene - Google Patents
Compuesto macrocíclico útil para tratar el cáncer y composición farmacéutica que lo contieneInfo
- Publication number
- UY39574A UY39574A UY0001039574A UY39574A UY39574A UY 39574 A UY39574 A UY 39574A UY 0001039574 A UY0001039574 A UY 0001039574A UY 39574 A UY39574 A UY 39574A UY 39574 A UY39574 A UY 39574A
- Authority
- UY
- Uruguay
- Prior art keywords
- pharmaceutical composition
- composition containing
- treat cancer
- compound useful
- macrocyclic compound
- Prior art date
Links
- 150000002678 macrocyclic compounds Chemical class 0.000 title abstract 4
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 201000011510 cancer Diseases 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/529—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim forming part of bridged ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed systems contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D515/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
- C07D515/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D515/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
- C07D515/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D515/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/14—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063126722P | 2020-12-17 | 2020-12-17 | |
| US202163279850P | 2021-11-16 | 2021-11-16 | |
| US202163284789P | 2021-12-01 | 2021-12-01 | |
| US202163289014P | 2021-12-13 | 2021-12-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UY39574A true UY39574A (es) | 2022-07-29 |
Family
ID=82058646
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UY0001039574A UY39574A (es) | 2020-12-17 | 2021-12-17 | Compuesto macrocíclico útil para tratar el cáncer y composición farmacéutica que lo contiene |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20240182487A1 (https=) |
| EP (1) | EP4262796A4 (https=) |
| JP (1) | JP2023553835A (https=) |
| KR (1) | KR20230121773A (https=) |
| AU (1) | AU2021401741A1 (https=) |
| CA (1) | CA3202770A1 (https=) |
| IL (1) | IL303419A (https=) |
| MX (1) | MX2023007162A (https=) |
| PY (1) | PY21110949A (https=) |
| UY (1) | UY39574A (https=) |
| WO (1) | WO2022133037A1 (https=) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2023283476A1 (en) * | 2022-06-08 | 2024-11-14 | Blossomhill Therapeutics, Inc. | Indazole macrocycles and their use |
| CA3258157A1 (en) * | 2022-06-08 | 2023-12-14 | Blossomhill Therapeutics, Inc. | Indazole-Containing Macrocycles and Their Use |
| JP2025524038A (ja) * | 2022-07-27 | 2025-07-25 | 上海和誉生物医薬科技有限公司 | 大環状ｅｇｆｒ阻害剤、その製造方法及び薬学における応用 |
| EP4655304A1 (en) * | 2023-02-22 | 2025-12-03 | Yuhan Corporation | Macrocyclic aminopyridine compounds as egfr inhibitors |
| JP2026507654A (ja) * | 2023-02-22 | 2026-03-04 | ユーハン・コーポレイション | Ｅｇｆｒ阻害剤としての大環状アミノピリジン化合物 |
| KR20250142978A (ko) * | 2023-02-22 | 2025-09-30 | 주식회사유한양행 | Egfr 억제제로서의 마크로시클릭 아미노피리딘 화합물 |
| EP4688750A1 (en) | 2023-04-06 | 2026-02-11 | Pfizer Inc. | Substituted indazole propionic acid derivative compounds and uses thereof as ampk activators |
| AU2024266587A1 (en) * | 2023-05-02 | 2025-09-11 | Blossomhill Therapeutics, Inc. | Egfr inhibitors for treating disease |
| EP4731213A2 (en) * | 2023-06-23 | 2026-04-29 | Blossomhill Therapeutics, Inc. | Combination therapy involving macrocyclic indazole compounds |
| WO2025122911A1 (en) * | 2023-12-07 | 2025-06-12 | Blossomhill Therapeutics, Inc. | Indazole macrocycle polymorphs |
| WO2025122859A1 (en) * | 2023-12-08 | 2025-06-12 | Blossomhill Therapeutics, Inc. | Indazole-based macrocyclic compounds |
| WO2025199438A1 (en) * | 2024-03-22 | 2025-09-25 | Blossomhill Therapeutics, Inc. | 7-azaindazole macrocycles and their use |
| WO2025245175A1 (en) * | 2024-05-22 | 2025-11-27 | Ajax Therapeutics, Inc. | Macrocyclic heteroaromatic inhibitors of jak2 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO3062B1 (ar) * | 2010-10-05 | 2017-03-15 | Lilly Co Eli | R)-(e)-2-(4-(2-(5-(1-(3، 5-داي كلورو بيريدين-4-يل)إيثوكسي)-1h-إندازول-3-يل)?ينيل)-1h-بيرازول-1-يل)إيثانول بلوري |
| DK2822953T5 (en) * | 2012-03-06 | 2017-09-11 | Pfizer | Macrocyclic derivatives for the treatment of proliferative diseases |
| EP3333157B1 (en) * | 2015-08-07 | 2020-12-23 | Harbin Zhenbao Pharmaceutical Co., Ltd. | Vinyl compounds as fgfr and vegfr inhibitors |
| CN111269245B (zh) * | 2018-12-04 | 2021-08-27 | 杭州百新生物医药科技有限公司 | 一种环状氨基嘧啶衍生物及其抑制激酶的活性和用途 |
| BR112021012057A2 (pt) * | 2018-12-21 | 2021-10-19 | Revolution Medicines, Inc. | Compostos que participam de ligação cooperativa e usos dos mesmos |
-
2021
- 2021-12-16 WO PCT/US2021/063721 patent/WO2022133037A1/en not_active Ceased
- 2021-12-16 US US18/257,166 patent/US20240182487A1/en active Pending
- 2021-12-16 AU AU2021401741A patent/AU2021401741A1/en active Pending
- 2021-12-16 KR KR1020237021826A patent/KR20230121773A/ko active Pending
- 2021-12-16 MX MX2023007162A patent/MX2023007162A/es unknown
- 2021-12-16 EP EP21907788.0A patent/EP4262796A4/en active Pending
- 2021-12-16 JP JP2023532465A patent/JP2023553835A/ja active Pending
- 2021-12-16 CA CA3202770A patent/CA3202770A1/en active Pending
- 2021-12-16 IL IL303419A patent/IL303419A/en unknown
- 2021-12-17 UY UY0001039574A patent/UY39574A/es unknown
- 2021-12-17 PY PY202121110949A patent/PY21110949A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20230121773A (ko) | 2023-08-21 |
| IL303419A (en) | 2023-08-01 |
| AU2021401741A1 (en) | 2023-06-29 |
| US20240182487A1 (en) | 2024-06-06 |
| WO2022133037A1 (en) | 2022-06-23 |
| EP4262796A4 (en) | 2025-04-02 |
| JP2023553835A (ja) | 2023-12-26 |
| EP4262796A1 (en) | 2023-10-25 |
| MX2023007162A (es) | 2023-06-29 |
| PY21110949A (es) | 2023-08-07 |
| TW202241911A (zh) | 2022-11-01 |
| AU2021401741A9 (en) | 2024-09-19 |
| CA3202770A1 (en) | 2022-06-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UY39574A (es) | Compuesto macrocíclico útil para tratar el cáncer y composición farmacéutica que lo contiene | |
| ECSP20033467A (es) | Compuestos macrocíclicos para tratar enfermedades | |
| MX2025000271A (es) | Inhibidores de kras de anillo fusionado para el tratamiento de enfermedades | |
| CO2022010460A2 (es) | Compuestos tricíclicos sustituidos | |
| CO2024001285A2 (es) | Compuestos tricíclicos como inhibidores de kras | |
| ECSP20069418A (es) | Compuestos heterocíclicos como inmunomoduladores | |
| DOP2018000257A (es) | Piridinas sustituidas con heteroarilo y métodos de uso | |
| DOP2018000222A (es) | Inhibidores de mcl1 macrocíclicos para tratar el cáncer antecedentes | |
| CO6710897A2 (es) | Derivados de poperdinona como inhibidores mdm2 para el tratamiento del cáncer | |
| CO6341623A2 (es) | Compuestos organicos | |
| MX381235B (es) | Análogos de éter fosfolipídico como portadores de fármacos dirigidos a cáncer. | |
| UY36702A (es) | Piridinas sustituidas y métodos de uso | |
| CL2023000061A1 (es) | Macrociclos y su uso | |
| UY39779A (es) | Compuestos macrocíclicos para tratar enfermedades | |
| MX2017012102A (es) | Agentes citotoxicos bifuncionales que contienen el farmacoforo de cti. | |
| CO2024006727A2 (es) | Compuestos y composiciones macrocíclicos, y métodos para preparar y utilizar los mismos | |
| CL2011000258A1 (es) | Compuestos derivados de fenilamino-isonicotinamida; inhibidores de mek; composicion farmaceutica y uso para el tratamiento de enfermedades hiperproliferativas tales como cancer e inflamacion. | |
| CO2022014837A2 (es) | Células t v delta1+ para el tratamiento de neoplasias mieloides | |
| CO2020003475A2 (es) | Sulfonas y sulfóxidos bicíclicos y métodos de uso de los mismos | |
| CR20240533A (es) | Macrociclos de indazol y su uso | |
| AR128109A1 (es) | Spiros y análogos relacionados para inhibir yap / taz-tead | |
| CO2025016647A2 (es) | Inhibidores de egfr para el tratamiento de enfermedades | |
| CO2022017969A2 (es) | Compuestos de imidazopiridazina con actividad como inhibidores de alk2 | |
| DOP2025000274A (es) | Inhibidores de egfr para el tratamiento de enfermedades | |
| CL2022002527A1 (es) | Células t v delta1 para el tratamiento de neoplasias mieloides |